Username

Password

Forgot Password?

Preview

Sign-in free and Explore the Exciting World of BiomedExperts:

Over 1.500.000 Profiles
More than 1.800 Organizations worldwide
State of the Art Network Visualizations

Manage your own Profile
Locate Experts in your Country/Region
Locate Experts in your 1. and 2. Level Network
Connect to Experts Worldwide

NetworkView

Roman Perez-Soler

This is a preview profile on BiomedExperts - the first literature-based scientific social network. It brings the right researchers together and allows them to collaborate online. Collexis and Dell provide the BiomedExperts network of +1.5 Million pre-calculated profiles free of charge to researchers worldwide.

Research Profile (preview)

Chemicals & Drugs

Living Beings

Mice

Disorders

Anatomy

Cultured Tumor Cells

Concepts & Ideas

Tissue Distribution

Physiology

Cell Survival

Procedures

Antitumor Drug Screening Assays

Sign-in to see full Profile

Network (preview)

Co-Publications
Name
41
Ling, Yi-He
26
Khokhar, Abdul
21
Zou, Yiyu
19
Priebe, Waldemar
17
Shin, Dong
14
Hong, Waun Ki
12
Glisson, Bonnie
10
Fossella, Frank
8
Lee, Jin
8
Murphy, WK
7
Kurie, Jonathan
6
Haigentz, Missak
5
Jiang, Jian-Dong
5
Lopez-Berestein, Gabriel
5
Khuri, Fadlo

Sign-in to see all Coauthors

Publications

TOP 3
Ling Yi-He; Li Tianhong; Perez-Soler Roman; Haigentz Missak
Activation of ER stress and inhibition of EGFR N-glycosylation by tunicamycin enhances susceptibility of human non-small cell lung cancer cells to erlotinib.
Ling Yi-He; Aracil Miguel; Jimeno José; Perez-Soler Roman; Zou Yiyu
Molecular pharmacodynamics of PM02734 (elisidepsin) as single agent and in combination with erlotinib; synergistic activity in human non-small cell lung cancer cell lines and xenograft models.
Li Tianhong; Perez-Soler Roman
Skin toxicities associated with epidermal growth factor receptor inhibitors.

Sign-in to see all Publications

Sign in free and see...

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the visualized research activity
of experts around the globe

Sign-in to see more

Geonetwork of Roman Perez-Soler (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

Sign-in to see more

All Publications

2009: Ling Yi-He; Li Tianhong; Perez-Soler Roman; Haigentz Missak
Activation of ER stress and inhibition of EGFR N-glycosylation by tunicamycin enhances susceptibility of human non-small cell lung cancer cells to erlotinib.
Cancer chemotherapy and pharmacology 2009;64(3):539-48.
2009: Ling Yi-He; Aracil Miguel; Jimeno José; Perez-Soler Roman; Zou Yiyu
Molecular pharmacodynamics of PM02734 (elisidepsin) as single agent and in combination with erlotinib; synergistic activity in human non-small cell lung cancer cell lines and xenograft models.
European journal of cancer (Oxford, England : 1990) 2009;45(10):1855-64.
2009: Li Tianhong; Perez-Soler Roman
Skin toxicities associated with epidermal growth factor receptor inhibitors.
Targeted oncology 2009;4(2):107-19.
2008: Ling Yi-He; Lin Ruoping; Perez-Soler Roman
Erlotinib induces mitochondrial-mediated apoptosis in human H3255 non-small-cell lung cancer cells with epidermal growth factor receptorL858R mutation through mitochondrial oxidative phosphorylation-dependent activation of BAX and BAK.
Molecular pharmacology 2008;74(3):793-806.
2008: Li Tianhong; Ling Yi-He; Perez-Soler Roman
Tumor dependence on the EGFR signaling pathway expressed by the p-EGFR:p-AKT ratio predicts erlotinib sensitivity in human non-small cell lung cancer (NSCLC) cells expressing wild-type EGFR gene.
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 2008;3(6):643-7.
2008: Jhawer Minaxi; Goel Sanjay; Wilson Andrew J; Montagna Cristina; Ling Yi-He; Byun Do-Sun; Nasser Shannon; Arango Diego; Shin Joongho; Klampfer Lidija; Augenlicht Leonard H; Perez-Soler Roman; Mariadason John M
PIK3CA mutation/PTEN expression status predicts response of colon cancer cells to the epidermal growth factor receptor inhibitor cetuximab.
Cancer research 2008;68(6):1953-61.
2007: Perez-Soler Roman; Van Cutsem Eric
Clinical research of EGFR inhibitors and related dermatologic toxicities.
Oncology (Williston Park, N.Y.) 2007;21(11 Suppl 5):10-6.
2007: Mitchell Edith P; Perez-Soler Roman; Van Cutsem Eric; Lacouture Mario E
Clinical presentation and pathophysiology of EGFRI dermatologic toxicities.
Oncology (Williston Park, N.Y.) 2007;21(11 Suppl 5):4-9.
2007: Piperdi Bilal; Ling Yi-He; Perez-Soler Roman
Schedule-dependent interaction between the proteosome inhibitor bortezomib and the EGFR-TK inhibitor erlotinib in human non-small cell lung cancer cell lines.
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 2007;2(8):715-21.
2007: Zou Yiyu; Tornos Carmen; Qiu Xuan; Lia Marie; Perez-Soler Roman
p53 aerosol formulation with low toxicity and high efficiency for early lung cancer treatment.
Clinical cancer research : an official journal of the American Association for Cancer Research 2007;13(16):4900-8.
2007: Perez-Soler Roman
Erlotinib: recent clinical results and ongoing studies in non small cell lung cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research 2007;13(15 Pt 2):s4589-92.
2007: Lynch Thomas J; Bonomi Philip D; Butts Charles; Davies Angela M; Engelman Jeffrey; Govindan Ramaswamy; Herbst Roy S; Heymach John V; Johnson Bruce E; Martins Renato G; Perez-Soler Roman; Riely Gregory J; Sandler Alan B; Sequist Lecia V; Socinski Mark A; Wong Kwok-Kin; Hart Carol S
Novel agents in the treatment of lung cancer: Fourth Cambridge Conference.
Clinical cancer research : an official journal of the American Association for Cancer Research 2007;13(15 Pt 2):s4583-8.
2007: Ling Yi-He; Li Tianhong; Yuan Ziqiang; Haigentz Missak; Weber Thomas K; Perez-Soler Roman
Erlotinib, an effective epidermal growth factor receptor tyrosine kinase inhibitor, induces p27KIP1 up-regulation and nuclear translocation in association with cell growth inhibition and G1/S phase arrest in human non-small-cell lung cancer cell lines.
Molecular pharmacology 2007;72(2):248-58.
2007: Li Tianhong; Ling Yi-He; Goldman I David; Perez-Soler Roman
Schedule-dependent cytotoxic synergism of pemetrexed and erlotinib in human non-small cell lung cancer cells.
Clinical cancer research : an official journal of the American Association for Cancer Research 2007;13(11):3413-22.
2007: Wittgen Bart P H; Kunst Peter W A; van der Born Kasper; van Wijk Atie W; Perkins Walter; Pilkiewicz Frank G; Perez-Soler Roman; Nicholson Susan; Peters Godefridus J; Postmus Pieter E
Phase I study of aerosolized SLIT cisplatin in the treatment of patients with carcinoma of the lung.
Clinical cancer research : an official journal of the American Association for Cancer Research 2007;13(8):2414-21.
2007: Goel Sanjay; Hidalgo Manuel; Perez-Soler Roman
EGFR inhibitor-mediated apoptosis in solid tumors.
Journal of experimental therapeutics & oncology 2007;6(4):305-20.
2006: Perez-Soler Roman
Rash as a surrogate marker for efficacy of epidermal growth factor receptor inhibitors in lung cancer.
Clinical lung cancer 2006;8 Suppl 1():S7-14.
2005: Lu Charles; Perez-Soler Roman; Piperdi Bilal; Walsh Garrett L; Swisher Stephen G; Smythe W Roy; Shin Hyung J; Ro Jae Y; Feng Lei; Truong Mylene; Yalamanchili Adiseshu; Lopez-Berestein Gabriel; Hong Waun K; Khokhar Abdul R; Shin Dong M
Phase II study of a liposome-entrapped cisplatin analog (L-NDDP) administered intrapleurally and pathologic response rates in patients with malignant pleural mesothelioma.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2005;23(15):3495-501.
2005: Dai Qun; Ling Yi-He; Lia Marie; Zou Yi-Yu; Kroog Glenn; Iwata Kenneth K; Perez-Soler Roman
Enhanced sensitivity to the HER1/epidermal growth factor receptor tyrosine kinase inhibitor erlotinib hydrochloride in chemotherapy-resistant tumor cell lines.
Clinical cancer research : an official journal of the American Association for Cancer Research 2005;11(4):1572-8.
2004: Perez-Soler Roman
Phase II clinical trial data with the epidermal growth factor receptor tyrosine kinase inhibitor erlotinib (OSI-774) in non-small-cell lung cancer.
Clinical lung cancer 2004;6 Suppl 1():S20-3.
2004: Hu Liang; Lee Merlin; Campbell Wendy; Perez-Soler Roman; Karpatkin Simon
Role of endogenous thrombin in tumor implantation, seeding, and spontaneous metastasis.
Blood 2004;104(9):2746-51.
2004: Lopez-Barcons Lluis A; Zhang Junhong; Siriwitayawan Gunching; Burke Thomas G; Perez-Soler Roman
The novel highly lipophilic topoisomerase I inhibitor DB67 is effective in the treatment of liver metastases of murine CT-26 colon carcinoma.
Neoplasia (New York, N.Y.) 2004;6(5):457-67.
2004: Perez-Soler Roman
The role of erlotinib (Tarceva, OSI 774) in the treatment of non-small cell lung cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research 2004;10(12 Pt 2):4238s-4240s.
2004: Lynch Thomas J; Adjei Alex A; Bunn Paul A; DuBois Raymond N; Gandara David R; Giaccone Giuseppe; Govindan Ramaswamy; Herbst Roy S; Johnson Bruce E; Khuri Fadlo R; Perez-Soler Roman; Rosell Rafael; Rowinsky Eric K; Sandler Alan B; Scagliotti Giorgio V; Schiller Joan H; Shapiro Geoffrey I; Socinski Mark A; Hart Carol S
Novel agents in the treatment of lung cancer: conference summary statement.
Clinical cancer research : an official journal of the American Association for Cancer Research 2004;10(12 Pt 2):4199s-4204s.
2004: Zhong Yun; Lopez-Barcons Lluis; Haigentz Missak; Ling Yi-He; Perez-Soler Roman
Exogenous expression of H-cadherin in CHO cells regulates contact inhibition of cell growth by inducing p21 expression.
International journal of oncology 2004;24(6):1573-9.
2004: Diaz Roberto; Lopez-Barcons Lluis; Ahn Daniel; Garcia-Espana Antonio; Yoon Andrew; Matthews Jeremy; Mangues Ramon; Perez-Soler Roman; Pellicer Angel
Complex effects of Ras proto-oncogenes in tumorigenesis.
Carcinogenesis 2004;25(4):535-9.
2004: Belbin Thomas J; Gaspar John; Haigentz Missak; Perez-Soler Roman; Keller Steven M; Prystowsky Michael B; Childs Geoffrey; Socci Nicholas D
Indirect measurements of differential gene expression with cDNA microarrays.
BioTechniques 2004;36(2):310-4.
2004: Glover Katrina Y; Perez-Soler Roman; Papadimitradopoulou Vassiliki A
A review of small-molecule epidermal growth factor receptor-specific tyrosine kinase inhibitors in development for non-small cell lung cancer.
Seminars in oncology 2004;31(1 Suppl 1):83-92.
2003: Ling Yi-He; Liebes Leonard; Zou Yiyu; Perez-Soler Roman
Reactive oxygen species generation and mitochondrial dysfunction in the apoptotic response to Bortezomib, a novel proteasome inhibitor, in human H460 non-small cell lung cancer cells.
The Journal of biological chemistry 2003;278(36):33714-23.
2003: Drobnjak Marija; Melamed Jonathan; Taneja Samir; Melzer Kate; Wieczorek Rosemary; Levinson Benjamin; Zeleniuch-Jacquotte Anne; Polsky David; Ferrara Jay; Perez-Soler Roman; Cordon-Cardo Carlos; Pagano Michele; Osman Iman
Altered expression of p27 and Skp2 proteins in prostate cancer of African-American patients.
Clinical cancer research : an official journal of the American Association for Cancer Research 2003;9(7):2613-9.
2003: Bulgaru Anca M; Mani Sridhar; Goel Sanjay; Perez-Soler Roman
Erlotinib (Tarceva): a promising drug targeting epidermal growth factor receptor tyrosine kinase.
Expert review of anticancer therapy 2003;3(3):269-79.
2003: Liu WenJing; Bulgaru Anca; Haigentz Missak; Stein C A; Perez-Soler Roman; Mani Sridhar
The BCL2-family of protein ligands as cancer drugs: the next generation of therapeutics.
Current medicinal chemistry. Anti-cancer agents 2003;3(3):217-23.
2003: Ling Yi-He; Liebes Leonard; Jiang Jian-Dong; Holland James F; Elliott Peter J; Adams Julian; Muggia Franco M; Perez-Soler Roman
Mechanisms of proteasome inhibitor PS-341-induced G(2)-M-phase arrest and apoptosis in human non-small cell lung cancer cell lines.
Clinical cancer research : an official journal of the American Association for Cancer Research 2003;9(3):1145-54.
2003: Haigentz Missak; Perez-Soler Roman
Chemopreventive therapeutics. Inhalation therapies for lung cancer and bronchial premalignancy.
Methods in molecular medicine 2003;75():771-80.
2002: Jiang Jian-Dong; Denner Larry; Ling Yi-He; Li Jian-Nong; Davis Ashley; Wang Yue; Li Yan; Roboz Julia; Wang Long-Gui; Perez-Soler Roman; Marcelli Marco; Bekesi George; Holland James F
Double blockade of cell cycle at g(1)-s transition and m phase by 3-iodoacetamido benzoyl ethyl ester, a new type of tubulin ligand.
Cancer research 2002;62(21):6080-8.
2002: Ling Yi-He; Jiang Jian-Dong; Holland James F; Perez-Soler Roman
Arsenic trioxide produces polymerization of microtubules and mitotic arrest before apoptosis in human tumor cell lines.
Molecular pharmacology 2002;62(3):529-38.
2002: Ling Yi-He; Liebes Leonard; Ng Bruce; Buckley Michael; Elliott Peter J; Adams Julian; Jiang Jian-Dong; Muggia Franco M; Perez-Soler Roman
PS-341, a novel proteasome inhibitor, induces Bcl-2 phosphorylation and cleavage in association with G2-M phase arrest and apoptosis.
Molecular cancer therapeutics 2002;1(10):841-9.
2002: Diaz Roberto; Ahn Daniel; Lopez-Barcons Lluis; Malumbres Marcos; Perez de Castro Ignacio; Lue Jeffrey; Ferrer-Miralles Neus; Mangues Ramon; Tsong Jerry; Garcia Roberto; Perez-Soler Roman; Pellicer Angel
The N-ras proto-oncogene can suppress the malignant phenotype in the presence or absence of its oncogene.
Cancer research 2002;62(15):4514-8.
2002: Goel Sanjay; Mani Sridhar; Perez-Soler Roman
Tyrosine kinase inhibitors: a clinical perspective.
Current oncology reports 2002;4(1):9-19.
2001: Ling Y H; Donato N J; Perez-Soler R
Sensitivity to topoisomerase I inhibitors and cisplatin is associated with epidermal growth factor receptor expression in human cervical squamous carcinoma ME180 sublines.
Cancer chemotherapy and pharmacology 2001;47(6):473-80.
2001: Zhong Y; Delgado Y; Gomez J; Lee S W; Perez-Soler R
Loss of H-cadherin protein expression in human non-small cell lung cancer is associated with tumorigenicity.
Clinical cancer research : an official journal of the American Association for Cancer Research 2001;7(6):1683-7.
2001: Shin D M; Donato N J; Perez-Soler R; Shin H J; Wu J Y; Zhang P; Lawhorn K; Khuri F R; Glisson B S; Myers J; Clayman G; Pfister D; Falcey J; Waksal H; Mendelsohn J; Hong W K
Epidermal growth factor receptor-targeted therapy with C225 and cisplatin in patients with head and neck cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research 2001;7(5):1204-13.
2001: Ling Y; Zhong Y; Perez-Soler R
Disruption of cell adhesion and caspase-mediated proteolysis of beta- and gamma-catenins and APC protein in paclitaxel-induced apoptosis.
Molecular pharmacology 2001;59(3):593-603.
2000: Perez-Soler R; Kemp B; Wu Q P; Mao L; Gomez J; Zeleniuch-Jacquotte A; Yee H; Lee J S; Jagirdar J; Ling Y H
Response and determinants of sensitivity to paclitaxel in human non-small cell lung cancer tumors heterotransplanted in nude mice.
Clinical cancer research : an official journal of the American Association for Cancer Research 2000;6(12):4932-8.
2000: Oh Y; Perez-Soler R; Fossella F V; Glisson B S; Kurie J; Walsh G L; Truong M; Shin D M
Phase II study of intravenous Doxil in malignant pleural mesothelioma.
Investigational new drugs 2000;18(3):243-5.
2000: Fox L E; Rosenthal R C; King R R; Levine P B; Vail D M; Helfand S C; MacEwen E G; Perez-Soler R; Calderwood-Mays M; Kurzman I D
Use of cis-bis-neodecanoato-trans-R,R-1,2-diaminocyclohexane platinum (II), a liposomal cisplatin analogue, in cats with oral squamous cell carcinoma.
American journal of veterinary research 2000;61(7):791-5.
2000: MacLean D S; Khokhar A R; Perez-Soler R
Neutron activation of NDDP, a liposomal platinum antitumor agent.
Cancer biotherapy & radiopharmaceuticals 2000;15(3):253-9.
2000: Zou Y; Zong G; Ling Y H; Perez-Soler R
Development of cationic liposome formulations for intratracheal gene therapy of early lung cancer.
Cancer gene therapy 2000;7(5):683-96.
2000: Maclean D S; Khokhar A R; Tyle P; Perez-Soler R
Intraliposomal chemical activation patterns of liposomal cis-bis-neodecanoato-trans-R,R-1,2-diaminocyclohexane platinum (II) (L-NDDP)-a potential antitumour agent.
Journal of microencapsulation 2000;17(3):307-22.
2000: Yen N; Ioannides C G; Xu K; Swisher S G; Lawrence D D; Kemp B L; El-Naggar A K; Cristiano R J; Fang B; Glisson B S; Hong W K; Khuri F R; Kurie J M; Lee J J; Lee J S; Merritt J A; Mukhopadhyay T; Nesbitt J C; Nguyen D; Perez-Soler R; Pisters K M; Putnam J B; Schrump D S; Shin D M; Walsh G L; Roth J A
Cellular and humoral immune responses to adenovirus and p53 protein antigens in patients following intratumoral injection of an adenovirus vector expressing wild-type. P53 (Ad-p53).
Cancer gene therapy 2000;7(4):530-6.
2000: Ling Y H; Zou Y; Perez-Soler R
Induction of senescence-like phenotype and loss of paclitaxel sensitivity after wild-type p53 gene transfection of p53-null human non-small cell lung cancer H358 cells.
Anticancer research 2000;20(2A):693-702.
2000: Nemunaitis J; Swisher S G; Timmons T; Connors D; Mack M; Doerksen L; Weill D; Wait J; Lawrence D D; Kemp B L; Fossella F; Glisson B S; Hong W K; Khuri F R; Kurie J M; Lee J J; Lee J S; Nguyen D M; Nesbitt J C; Perez-Soler R; Pisters K M; Putnam J B; Richli W R; Shin D M; Walsh G L; Merritt J; Roth J
Adenovirus-mediated p53 gene transfer in sequence with cisplatin to tumors of patients with non-small-cell lung cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2000;18(3):609-22.
2000: Donato N J; Perez M; Kang H; Siddik Z H; Ling Y H; Perez-Soler R
EGF receptor and p21WAF1 expression are reciprocally altered as ME-180 cervical carcinoma cells progress from high to low cisplatin sensitivity.
Clinical cancer research : an official journal of the American Association for Cancer Research 2000;6(1):193-202.
2000: Booser D J; Perez-Soler R; Cossum P; Esparza-Guerra L; Wu Q P; Zou Y; Priebe W; Hortobagyi G N
Phase I study of liposomal annamycin.
Cancer chemotherapy and pharmacology 2000;46(5):427-32.
1999: Glisson B S; Kurie J M; Perez-Soler R; Fox N J; Murphy W K; Fossella F V; Lee J S; Ross M B; Nyberg D A; Pisters K M; Shin D M; Hong W K
Cisplatin, etoposide, and paclitaxel in the treatment of patients with extensive small-cell lung carcinoma.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1999;17(8):2309-15.
1999: Swisher S G; Roth J A; Nemunaitis J; Lawrence D D; Kemp B L; Carrasco C H; Connors D G; El-Naggar A K; Fossella F; Glisson B S; Hong W K; Khuri F R; Kurie J M; Lee J J; Lee J S; Mack M; Merritt J A; Nguyen D M; Nesbitt J C; Perez-Soler R; Pisters K M; Putnam J B; Richli W R; Savin M; Schrump D S; Shin D M; Shulkin A; Walsh G L; Wait J; Weill D; Waugh M K
Adenovirus-mediated p53 gene transfer in advanced non-small-cell lung cancer.
Journal of the National Cancer Institute 1999;91(9):763-71.
1999: Fox L E; Toshach K; Calderwood-Mays M; Khokhar A R; Kubilis P; Perez-Soler R; MacEwen E G
Evaluation of toxicosis of liposome-encapsulated cis-bis-neodecanoato-trans-R,R-1,2-diaminocyclohexane platinum (II) in clinically normal cats.
American journal of veterinary research 1999;60(2):257-63.
1998: Jiang J D; Davis A S; Middleton K; Ling Y H; Perez-Soler R; Holland J F; Bekesi J G
3-(Iodoacetamido)-benzoylurea: a novel cancericidal tubulin ligand that inhibits microtubule polymerization, phosphorylates bcl-2, and induces apoptosis in tumor cells.
Cancer research 1998;58(23):5389-95.
1998: Ling Y H; Yang Y; Tornos C; Singh B; Perez-Soler R
Paclitaxel-induced apoptosis is associated with expression and activation of c-Mos gene product in human ovarian carcinoma SKOV3 cells.
Cancer research 1998;58(16):3633-40.
1998: Zou Y; Zong G; Ling Y H; Hao M M; Lozano G; Hong W K; Perez-Soler R
Effective treatment of early endobronchial cancer with regional administration of liposome-p53 complexes.
Journal of the National Cancer Institute 1998;90(15):1130-7.
1998: Ling Y H; Tornos C; Perez-Soler R
Phosphorylation of Bcl-2 is a marker of M phase events and not a determinant of apoptosis.
The Journal of biological chemistry 1998;273(30):18984-91.
1998: Ling Y H; Consoli U; Tornos C; Andreeff M; Perez-Soler R
Accumulation of cyclin B1, activation of cyclin B1-dependent kinase and induction of programmed cell death in human epidermoid carcinoma KB cells treated with taxol.
International journal of cancer. Journal international du cancer 1998;75(6):925-32.
1998: Fueyo J; Gomez-Manzano C; Puduvalli V K; Martin-Duque P; Perez-Soler R; Levin V A; Yung W K; Kyritsis A P
Adenovirus-mediated p16 transfer to glioma cells induces G1 arrest and protects from paclitaxel and topotecan: implications for therapy.
International journal of oncology 1998;12(3):665-9.
1998: Glisson B; Komaki R; Lee J S; Shin D M; Fossella F; Murphy W K; Kurie J; Perez-Soler R; Schea R; Vadhan-Raj S
Integration of filgrastim into chemoradiation for limited small cell lung cancer: a Phase I study.
International journal of radiation oncology, biology, physics 1998;40(2):331-6.
1998: Glisson B; Lee J S; Palmer J; Fossella F; Shin D M; Murphy W K; Perez-Soler R; Hong W K
Cisplatin, ifosfamide, and prolonged oral etoposide in the treatment of patients with extensive small cell lung carcinoma.
Cancer 1998;82(2):301-8.
1998: Shade R J; Pisters K M; Huber M H; Fossella F; Perez-Soler R; Shin D M; Kurie J; Glisson B; Lippman S; Lee J S
Phase I study of paclitaxel administered by ten-day continuous infusion.
Investigational new drugs 1998;16(3):237-43.
1997: Perez-Soler R
Topotecan in the treatment of non-small cell lung cancer.
Seminars in oncology 1997;24(6 Suppl 20):S20-34-S20-41.
1997: Perez-Soler R; Shin D M; Siddik Z H; Murphy W K; Huber M; Lee S J; Khokhar A R; Hong W K
Phase I clinical and pharmacological study of liposome-entrapped NDDP administered intrapleurally in patients with malignant pleural effusions.
Clinical cancer research : an official journal of the American Association for Cancer Research 1997;3(3):373-9.
1997: Perez-Soler R; Neamati N; Zou Y; Schneider E; Doyle L A; Andreeff M; Priebe W; Ling Y H
Annamycin circumvents resistance mediated by the multidrug resistance-associated protein (MRP) in breast MCF-7 and small-cell lung UMCC-1 cancer cell lines selected for resistance to etoposide.
International journal of cancer. Journal international du cancer 1997;71(1):35-41.
1997: Chaires J B; Leng F; Przewloka T; Fokt I; Ling Y H; Perez-Soler R; Priebe W
Structure-based design of a new bisintercalating anthracycline antibiotic.
Journal of medicinal chemistry 1997;40(3):261-6.
1997: Fossella F V; Lippman S M; Shin D M; Tarassoff P; Calayag-Jung M; Perez-Soler R; Lee J S; Murphy W K; Glisson B; Rivera E; Hong W K
Maximum-tolerated dose defined for single-agent gemcitabine: a phase I dose-escalation study in chemotherapy-naive patients with advanced non-small-cell lung cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1997;15(1):310-6.
1996: Perez-Soler R; Glisson B S; Lee J S; Fossella F V; Murphy W K; Shin D M; Hong W K
Treatment of patients with small-cell lung cancer refractory to etoposide and cisplatin with the topoisomerase I poison topotecan.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1996;14(10):2785-90.
1996: Consoli U; Priebe W; Ling Y H; Mahadevia R; Griffin M; Zhao S; Perez-Soler R; Andreeff M
The novel anthracycline annamycin is not affected by P-glycoprotein-related multidrug resistance: comparison with idarubicin and doxorubicin in HL-60 leukemia cell lines.
Blood 1996;88(2):633-44.
1996: Ling Y H; el-Naggar A K; Priebe W; Perez-Soler R
Cell cycle-dependent cytotoxicity, G2/M phase arrest, and disruption of p34cdc2/cyclin B1 activity induced by doxorubicin in synchronized P388 cells.
Molecular pharmacology 1996;49(5):832-41.
1996: Perez-Soler R; Fossella F V; Glisson B S; Lee J S; Murphy W K; Shin D M; Kemp B L; Lee J J; Kane J; Robinson R A; Lippman S M; Kurie J M; Huber M H; Raber M N; Hong W K
Phase II study of topotecan in patients with advanced non-small-cell lung cancer previously untreated with chemotherapy.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1996;14(2):503-13.
1996: Zou Y; Priebe W; Perez-Soler R
Lyophilized preliposomal formulation of the non-cross-resistant anthracycline annamycin: effect of surfactant on liposome formation, stability and size.
Cancer chemotherapy and pharmacology 1996;39(1-2):103-8.
1996: Han I; Khokhar A R; Perez-Soler R
Intraliposomal conversion of lipophilic cis-bis-carboxylato-trans-R,R-1,2-diaminocyclohexane-platinum (II) complexes into cis-bis-dichloro-trans-R,R-1,2-diaminocyclohexane-platinum (II).
Cancer chemotherapy and pharmacology 1996;39(1-2):17-24.
1996: Gaspar M M; Perez-Soler R; Cruz M E
Biological characterization of L-asparaginase liposomal formulations.
Cancer chemotherapy and pharmacology 1996;38(4):373-7.
1996: Sugarman S M; Zou Y; Wasan K; Poirot K; Kumi R; Reddy S; Perez-Soler R
Lipid-complexed camptothecin: formulation and initial biodistribution and antitumor activity studies.
Cancer chemotherapy and pharmacology 1996;37(6):531-8.
1996: Mori A; Wu S P; Han I; Khokhar A R; Perez-Soler R; Huang L
In vivo antitumor activity of cis-bis-neodecanoato-trans-R,R-1, 2-diaminocyclohexane platinum(II) formulated in long-circulating liposomes.
Cancer chemotherapy and pharmacology 1996;37(5):435-44.
1995: Zou Y; Priebe W; Stephens L C; Perez-Soler R
Preclinical toxicity of liposome-incorporated annamycin: selective bone marrow toxicity with lack of cardiotoxicity.
Clinical cancer research : an official journal of the American Association for Cancer Research 1995;1(11):1369-74.
1995: Wasan K M; Perez-Soler R
Distribution of free and liposomal annamycin within human plasma is regulated by plasma triglyceride concentrations but not by lipid transfer protein.
Journal of pharmaceutical sciences 1995;84(9):1094-100.
1995: Zou Y; Ling Y H; Reddy S; Priebe W; Perez-Soler R
Effect of vesicle size and lipid composition on the in vivo tumor selectivity and toxicity of the non-cross-resistant anthracycline annamycin incorporated in liposomes.
International journal of cancer. Journal international du cancer 1995;61(5):666-71.
1995: Ling Y H; Zou Y; Priebe W; Perez-Soler R
Partial circumvention of multi-drug resistance by annamycin is associated with comparable inhibition of DNA synthesis in the nuclear matrix of sensitive and resistant cells.
International journal of cancer. Journal international du cancer 1995;61(3):402-8.
1995: Fossella F V; Lee J S; Shin D M; Calayag M; Huber M; Perez-Soler R; Murphy W K; Lippman S; Benner S; Glisson B
Phase II study of docetaxel for advanced or metastatic platinum-refractory non-small-cell lung cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1995;13(3):645-51.
1995: Li S; Khokhar A R; Perez-Soler R; Huang L
Improved antitumor activity of cis-Bis-neodecanoato-trans-R,R-1,2- diaminocyclohexaneplatinum (II) entrapped in long-circulating liposomes.
Oncology research 1995;7(12):611-7.
1994: Solary E; Ling Y H; Perez-Soler R; Priebe W; Pommier Y
Hydroxyrubicin, a deaminated derivative of doxorubicin, inhibits mammalian DNA topoisomerase II and partially circumvents multidrug resistance.
International journal of cancer. Journal international du cancer 1994;58(1):85-94.
1994: Sampedro F; Partika J; Santalo P; Molins-Pujol A M; Bonal J; Perez-Soler R
Liposomes as carriers of different new lipophilic antitumour drugs: a preliminary report.
Journal of microencapsulation 1994;11(3):309-18.
1994: Perez-Soler R; Donato N J; Shin D M; Rosenblum M G; Zhang H Z; Tornos C; Brewer H; Chan J C; Lee J S; Hong W K
Tumor epidermal growth factor receptor studies in patients with non-small-cell lung cancer or head and neck cancer treated with monoclonal antibody RG 83852.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1994;12(4):730-9.
1994: Zou Y; Ling Y H; Van N T; Priebe W; Perez-Soler R
Antitumor activity of free and liposome-entrapped annamycin, a lipophilic anthracycline antibiotic with non-cross-resistance properties.
Cancer research 1994;54(6):1479-84.
1994: Han I; Ling Y H; Khokhar A R; Perez-Soler R
Cell death and DNA fragmentation induced by liposomal platinum(II) complex, L-NDDP in A2780 and A2780/PDD cells.
Anticancer research 1994;14(2A):421-6.
1994: Han I; Nguyen T; Yang L Y; Khokhar A R; Perez-Soler R
Cellular accumulation and DNA damage induced by liposomal cis-bis-neodecanoato-trans-R,R-1,2-diaminocyclohexaneplatinum+ ++(II) in LoVo and LoVo/PDD cells.
Anti-cancer drugs 1994;5(1):64-8.
1994: Perez-Soler R; Francis K; al-Baker S; Pilkiewicz F; Khokhar A R
Preparation and characterization of liposomes containing a lipophilic cisplatin derivative for clinical use.
Journal of microencapsulation 1994;11(1):41-54.
1994: Perez-Soler R; Han I; al-Baker S; Khokhar A R
Lipophilic platinum complexes entrapped in liposomes: improved stability and preserved antitumor activity with complexes containing linear alkyl carboxylato leaving groups.
Cancer chemotherapy and pharmacology 1994;33(5):378-84.
1994: Perez-Soler R; Ling Y H; Zou Y; Priebe W
Cellular pharmacology of the partially non-cross-resistant anthracycline annamycin entrapped in liposomes in KB and KB-V1 cells.
Cancer chemotherapy and pharmacology 1994;34(2):109-18.
1994: Jorge J C; Perez-Soler R; Morais J G; Cruz M E
Liposomal palmitoyl-L-asparaginase: characterization and biological activity.
Cancer chemotherapy and pharmacology 1994;34(3):230-4.
1994: Shin D M; Holoye P Y; Forman A; Winn R; Perez-Soler R; Dakhil S; Rosenthal J; Raber M N; Hong W K
Phase II clinical trial of didemnin B in previously treated small cell lung cancer.
Investigational new drugs 1994;12(3):243-9.
1993: Zou Y; Hayman A; Priebe W; Perez-Soler R
Quantitative analysis of the lipophilic doxorubicin analogue annamycin in plasma and tissue samples by reversed-phase chromatography.
Journal of pharmaceutical sciences 1993;82(11):1151-4.
1993: Priebe W; Perez-Soler R
Design and tumor targeting of anthracyclines able to overcome multidrug resistance: a double-advantage approach.
Pharmacology & therapeutics 1993;60(2):215-34.
1993: Han I; Ling Y H; al-Baker S; Khokhar A R; Perez-Soler R
Cellular pharmacology of liposomal cis-bis-neodecanoato-trans-R,R-1,2-diaminocyclohexaneplatinum(II) in A2780/S and A2780/PDD cells.
Cancer research 1993;53(20):4913-9.
1993: Ling Y H; Perez-Soler R; Tseng M T
Effect of DNA topoisomerase I inhibitor, 10-hydroxycamptothecin, on the structure and function of nuclei and nuclear matrix in bladder carcinoma MBT-2 cells.
Anticancer research 1993;13(5A):1613-7.
1993: Zou Y; Yamagishi M; Horikoshi I; Ueno M; Gu X; Perez-Soler R
Enhanced therapeutic effect against liver W256 carcinosarcoma with temperature-sensitive liposomal adriamycin administered into the hepatic artery.
Cancer research 1993;53(13):3046-51.
1993: Ling Y H; Priebe W; Perez-Soler R
Apoptosis induced by anthracycline antibiotics in P388 parent and multidrug-resistant cells.
Cancer research 1993;53(8):1845-52.
1993: Ling Y H; Priebe W; Yang L Y; Burke T G; Pommier Y; Perez-Soler R
In vitro cytotoxicity, cellular pharmacology, and DNA lesions induced by annamycin, an anthracycline derivative with high affinity for lipid membranes.
Cancer research 1993;53(7):1583-9.
1993: Priebe W; Van N T; Burke T G; Perez-Soler R
Removal of the basic center from doxorubicin partially overcomes multidrug resistance and decreases cardiotoxicity.
Anti-cancer drugs 1993;4(1):37-48.
1993: Zou Y; Priebe W; Ling Y H; Perez-Soler R
Organ distribution and tumor uptake of annamycin, a new anthracycline derivative with high affinity for lipid membranes, entrapped in multilamellar vesicles.
Cancer chemotherapy and pharmacology 1993;32(3):190-6.
1993: Zou Y; Horikoshi I; Kasagi T; Gu X; Perez-Soler R
Organ distribution and antitumor activity of free and liposomal doxorubicin injected into the hepatic artery.
Cancer chemotherapy and pharmacology 1993;31(4):313-8.
1992: Perez-Soler R; Khokhar A R
Lipophilic cisplatin analogues entrapped in liposomes: role of intraliposomal drug activation in biological activity.
Cancer research 1992;52(22):6341-7.
1992: al-Baker S; Perez-Soler R; Khokhar A R
Synthesis and biological studies of new lipid-soluble cisplatin analogues entrapped in liposomes.
Journal of inorganic biochemistry 1992;47(2):99-108.
1992: Zou Y; Horikoshi I; Ueno M; Gu X; Perez-Soler R
Targeting liver tumors by administering liposomal doxorubicin into the hepatic artery.
International journal of cancer. Journal international du cancer 1992;51(2):232-7.
1992: Khokhar A R; al-Baker S; Perez-Soler R
Toxicity and efficacy studies on a series of lipid-soluble dineodecanoato(trans-R,R- and trans-S,S-1,2-diaminocyclohexane) platinum (II) complexes entrapped in liposomes.
Anti-cancer drugs 1992;3(2):95-100.
1992: Priebe W; Neamati N; Perez-soler R
3'-Hydroxyesorubicin halogenated at C-2'.
The Journal of antibiotics 1992;45(3):386-93.
1992: Perez-Soler R; Priebe W
Liposomal formulation and antitumor activity of 14-O-palmitoyl-hydroxyrubicin.
Cancer chemotherapy and pharmacology 1992;30(4):267-71.
1992: Vadiei K; Siddik Z H; Khokhar A R; al-Baker S; Sampedro F; Perez-Soler R
Pharmacokinetics of liposome-entrapped cis-bis-neodecanoato-trans-R,R-1,2-diaminocyclohexane platinum(II) and cisplatin given i.v. and i.p. in the rat.
Cancer chemotherapy and pharmacology 1992;30(5):365-9.
1992: Sugarman S M; Perez-Soler R
Liposomes in the treatment of malignancy: a clinical perspective.
Critical reviews in oncology/hematology 1992;12(3):231-42.
1991: Vadiei K; Lopez-Berestein G; Perez-Soler R; Luke D R
Tissue distribution and in vivo immunosuppressive activity of liposomal cyclosporine.
Drug metabolism and disposition: the biological fate of chemicals 1991;19(6):1147-51.
1991: Khokhar A R; al-Baker S; Brown T; Perez-Soler R
Chemical and biological studies on a series of lipid-soluble (trans-(R,R)- and -(S,S)-1,2-diaminocyclohexane)platinum(II) complexes incorporated in liposomes.
Journal of medicinal chemistry 1991;34(1):325-9.
1990: Priebe W; Neamati N; Perez-Soler R
3'-Hydroxyesorubicin. Synthesis and antitumor activity.
The Journal of antibiotics 1990;43(7):838-46.
1990: Perez-Soler R; Lopez-Berestein G; Lautersztain J; al-Baker S; Francis K; Macias-Kiger D; Raber M N; Khokhar A R
Phase I clinical and pharmacological study of liposome-entrapped cis-bis-neodecanoato-trans-R,R-1,2-diaminocyclohexane platinum(II).
Cancer research 1990;50(14):4254-9.
1990: Perez-Soler R; Priebe W
Anthracycline antibiotics with high liposome entrapment: structural features and biological activity.
Cancer research 1990;50(14):4260-6.
1989: Perez-Soler R
Liposomes as carriers of antitumor agents: toward a clinical reality.
Cancer treatment reviews 1989;16(2):67-82.
1989: Perez-Soler R; Lautersztain J; Stephens L C; Wright K; Khokhar A R
Preclinical toxicity and pharmacology of liposome-entrapped cis-bis-neodecanoato-trans-R,R-1,2-diaminocyclohexane platinum(II).
Cancer chemotherapy and pharmacology 1989;24(1):1-8.
1989: Khokhar A R; al-Baker S; Krakoff I H; Perez-Soler R
Toxicity and antitumor activity of cis-bis-carboxylato(trans-R,R-1,2-diaminocyclohexane) platinum(II) complexes entrapped in liposomes.
Cancer chemotherapy and pharmacology 1989;23(4):219-24.
1988: Khokhar A R; Al-Baker S; Perez-Soler R
Toxicity and anti-tumor activity of hydrophobic diammine and diaminocyclohexane platinum complexes entrapped in multilamellar vesicles.
Anti-cancer drug design 1988;3(3):177-84.
1988: Perez-Soler R; Yang L Y; Drewinko B; Lauterzstain J; Khokhar A R
Increased cytotoxicity and reversal of resistance to cis-diamminedichloro-platinum(II) with entrapment of cis-Bis-neodecanoato-trans-R,R-1,2-diaminocyclohexaneplatinum (II) in multilamellar lipid vesicles.
Cancer research 1988;48(16):4509-12.
1988: Lautersztain J; Perez-Soler R; Turpin J; Khokhar A R; Siddik Z H; Schmidt K; Lopez-Berestein G
Cellular pharmacology of liposomal cis-bis-neodecanoato-trans-R,R-1,2-diaminocyclohexaneplatinum (II) in mouse resident peritoneal macrophages, Kupffer cells, and hepatocytes.
Cancer research 1988;48(5):1300-6.
1988: Khokhar A R; Wright K; Siddik Z H; Perez-Soler R
Organ distribution and tumor uptake of liposome entrapped cis-bis-neodecanoato trans-R, R-1,2 diaminocyclohexane platinum (II) administered intravenously and into the proper hepatic artery.
Cancer chemotherapy and pharmacology 1988;22(3):223-7.
1987: Perez-Soler R; Khokhar A R; Lopez-Berestein G
Treatment and prophylaxis of experimental liver metastases of M5076 reticulosarcoma with cis-bis-neodecanoato-trans-R,R-1,2-diaminocyclohexaneplatinum (II) encapsulated in multilamellar vesicles.
Cancer research 1987;47(24 Pt 1):6462-6.
1987: Perez-Soler R; Khokhar A R; Lautersztain J; Mitchell P A; Schmidt K L
Ultrastructural and freeze fracture localization of multilamellar liposomes containing a lipophilic cisplatin analogue in normal tissues and liver metastases of M5076 reticulosarcoma.
Cancer drug delivery 1987;4(2):75-88.
1986: Perez-Soler R; Khokhar A R; Hacker M P; Lopez-Berestein G
Toxicity and antitumor activity of cis-bis-cyclopentenecarboxylato-1,2-diaminocyclohexane platinum(II) encapsulated in multilamellar vesicles.
Cancer research 1986;46(12 Pt 1):6269-73.
1986: Perez-Soler R; Khokhar A R; Claringbold P; Kasi L P; Lopez-Berestein G
Effects on the monocyte-macrophage system and antitumor activity against L1210 leukemia of cis-bis-cyclopentenecarboxylato-trans-R,R-1,2-diaminocyclohexane -platinum (II) encapsulated in multilamellar vesicles.
Journal of the National Cancer Institute 1986;77(5):1137-43.
1986: Perez-Soler R; Smith T L; Cabanillas F
Central nervous system prophylaxis with combined intravenous and intrathecal methotrexate in diffuse lymphoma of aggressive histologic type.
Cancer 1986;57(5):971-7.
1986: Murray J L; Perez-Soler R; Bywaters D; Hersh E M
Decreased adenosine deaminase (ADA) and 5'nucleotidase (5NT) activity in peripheral blood T cells in Hodgkin disease.
American journal of hematology 1986;21(1):57-66.
1986: Lautersztain J; Perez-Soler R; Khokhar A R; Newman R A; Lopez-Berestein G
Pharmacokinetics and tissue distribution of liposome-encapsulated cis-bis-N-decyl-iminodiacetato-1,2-diaminocyclohexane-platinum (II).
Cancer chemotherapy and pharmacology 1986;18(2):93-7.
1985: Perez-Soler R; Esteban R; Allende E; Tornos Salomo C; Julia A; Guardia J
Liver involvement in multiple myeloma.
American journal of hematology 1985;20(1):25-9.
1985: Perez-Soler R; Lopez-Berestein G; Kasi L P; Cabanillas F; Jahns M; Glenn H; Hersh E M; Haynie T
Distribution of technetium-99m-labeled multilamellar liposomes in patients with Hodgkin's disease.
Journal of nuclear medicine : official publication, Society of Nuclear Medicine 1985;26(7):743-9.
1985: Perez-Soler R; Lopez-Berestein G; Cabanillas F; McLaughlin P; Hersh E M
Superoxide anion (O-2) production by peripheral blood monocytes in Hodgkin's disease and malignant lymphoma.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1985;3(5):641-5.
1985: Perez-Soler R; Lopez-Berestein G; Jahns M; Wright K; Kasi L P
Distribution of radiolabeled multilamellar liposomes injected intralymphatically and subcutaneously.
International journal of nuclear medicine and biology 1985;12(4):261-6.
1984: Perez-Soler R; McLaughlin P; Velasquez W S; Hagemeister F B; Zornoza J; Manning J T; Fuller L M; Cabanillas F
Clinical features and results of management of superior vena cava syndrome secondary to lymphoma.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1984;2(4):260-6.
1984: Merino J; Perez-Soler R; Luna M; Cabanillas F
Benign fibrous histiocytoma in Hodgkin's disease.
Cancer investigation 1984;2(5):347-50.
1981: Perez-Soler R; Cervantes M; Segura R M; Esteban R; Pascual C; Guardia J
Serum glutamate dehydrogenase in alcoholic liver disease.
British medical journal (Clinical research ed.) 1981;283(6302):1332.
1981: Perez-Soler R; Esteban R; Guardia J
Urinary monoclonal immunoglobulin in multiple myeloma.
Annals of internal medicine 1981;94(1):140.

Sign-in to see more